Market Cap 1.24B
Revenue (ttm) 75.62M
Net Income (ttm) -72.70M
EPS (ttm) N/A
PE Ratio 59.88
Forward PE N/A
Profit Margin -96.14%
Debt to Equity Ratio 0.00
Volume 733,700
Avg Vol 1,761,980
Day's Range N/A - N/A
Shares Out 65.12M
Stochastic %K 71%
Beta 1.61
Analysts Strong Sell
Price Target $33.80

Company Profile

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of i...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 949 2643
Address:
321 Harrison Avenue, Suite 900, Boston, United States
LabPsycho
LabPsycho Feb. 19 at 9:47 PM
$GLUE Recent ~ $300M offering plus another $100M announced last week ? Hmmm? https://www.sec.gov/Archives/edgar/data/1826457/000119312526046690/d72009ds3asr.htm
1 · Reply
MuchMillions
MuchMillions Feb. 19 at 5:49 PM
$GLUE big move coming next week
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 6:24 PM
$GLUE Current Stock Price: $17.94 Contracts to trade: $17.5 GLUE Feb 20 2026 Call Entry: $0.50 Exit: $0.71 ROI: 41% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
1 · Reply
LabPsycho
LabPsycho Feb. 13 at 9:27 PM
$GLUE @oneyedjacks Look at the 1 yr chart...this thing is up a zillion percent in a few months. I dont think $10 is unreasonable...many still will have a double at that price. The offering at the peak is a nice touch but many retrace to half that over time...but I think GLUE might be different. Good luck
0 · Reply
oneyedjacks
oneyedjacks Feb. 13 at 9:09 PM
$GLUE support anywhere?
0 · Reply
cheruskian
cheruskian Feb. 6 at 3:51 AM
$GLUE this person has no clue (pun enforcement intended) about the technology that is working under the hood in this org.
0 · Reply
LabPsycho
LabPsycho Feb. 5 at 6:13 PM
$GLUE @BuckeyeInvestor Unlike every other of the dozens of bioturds and Wealth Transfer Vehicles on my list, GLUE is the only one that did not do the massive InstaDilution on the Novartis news. All the others did a huge dilution a nanosecond after releasing any postive news the past 3 years - talk about (IMO illegal) trading on insider information when institutions buy in private placement the same time the news is released. Really...they did all their due diligence in that 1 second and coughed up millions? Anyhow...I digress. GLUE did not dilute when the stock doubled, or trippled or even 4X ! Long term this looks good (see my molecular dynamic simulation posted last summer bringing their Science Cover article to life with atomically accurate precision - and IMO, my best work yet! But I expect a retrace of a couple $ before potentially climbing above their offering price. Good luck.
0 · Reply
oneyedjacks
oneyedjacks Feb. 5 at 1:37 PM
$GLUE 20% haircut for that $24 direct placement, expect them to be buying more
0 · Reply
BuckeyeInvestor
BuckeyeInvestor Feb. 4 at 7:54 PM
$GLUE small add today. Simply too many things going for this company that I love to stop myself
1 · Reply
monoksop
monoksop Feb. 4 at 6:11 PM
$GLUE Small starter here.
0 · Reply
Latest News on GLUE
Why Is Monte Rosa Stock Trading Higher Today?

Dec 16, 2025, 2:37 PM EST - 2 months ago

Why Is Monte Rosa Stock Trading Higher Today?


Monte Rosa: Looking Mispriced After Big Pharma Validation

Nov 30, 2025, 4:36 AM EST - 3 months ago

Monte Rosa: Looking Mispriced After Big Pharma Validation


This Biotech Stock Has Doubled Its Value Today—Here's Why

Oct 28, 2024, 3:06 PM EDT - 1 year ago

This Biotech Stock Has Doubled Its Value Today—Here's Why


Monte Rosa Therapeutics Announces Leadership Team Promotions

May 30, 2024, 7:00 AM EDT - 1 year ago

Monte Rosa Therapeutics Announces Leadership Team Promotions


LabPsycho
LabPsycho Feb. 19 at 9:47 PM
$GLUE Recent ~ $300M offering plus another $100M announced last week ? Hmmm? https://www.sec.gov/Archives/edgar/data/1826457/000119312526046690/d72009ds3asr.htm
1 · Reply
MuchMillions
MuchMillions Feb. 19 at 5:49 PM
$GLUE big move coming next week
1 · Reply
BillionerOfKing
BillionerOfKing Feb. 16 at 6:24 PM
$GLUE Current Stock Price: $17.94 Contracts to trade: $17.5 GLUE Feb 20 2026 Call Entry: $0.50 Exit: $0.71 ROI: 41% Hold ~26 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
1 · Reply
LabPsycho
LabPsycho Feb. 13 at 9:27 PM
$GLUE @oneyedjacks Look at the 1 yr chart...this thing is up a zillion percent in a few months. I dont think $10 is unreasonable...many still will have a double at that price. The offering at the peak is a nice touch but many retrace to half that over time...but I think GLUE might be different. Good luck
0 · Reply
oneyedjacks
oneyedjacks Feb. 13 at 9:09 PM
$GLUE support anywhere?
0 · Reply
cheruskian
cheruskian Feb. 6 at 3:51 AM
$GLUE this person has no clue (pun enforcement intended) about the technology that is working under the hood in this org.
0 · Reply
LabPsycho
LabPsycho Feb. 5 at 6:13 PM
$GLUE @BuckeyeInvestor Unlike every other of the dozens of bioturds and Wealth Transfer Vehicles on my list, GLUE is the only one that did not do the massive InstaDilution on the Novartis news. All the others did a huge dilution a nanosecond after releasing any postive news the past 3 years - talk about (IMO illegal) trading on insider information when institutions buy in private placement the same time the news is released. Really...they did all their due diligence in that 1 second and coughed up millions? Anyhow...I digress. GLUE did not dilute when the stock doubled, or trippled or even 4X ! Long term this looks good (see my molecular dynamic simulation posted last summer bringing their Science Cover article to life with atomically accurate precision - and IMO, my best work yet! But I expect a retrace of a couple $ before potentially climbing above their offering price. Good luck.
0 · Reply
oneyedjacks
oneyedjacks Feb. 5 at 1:37 PM
$GLUE 20% haircut for that $24 direct placement, expect them to be buying more
0 · Reply
BuckeyeInvestor
BuckeyeInvestor Feb. 4 at 7:54 PM
$GLUE small add today. Simply too many things going for this company that I love to stop myself
1 · Reply
monoksop
monoksop Feb. 4 at 6:11 PM
$GLUE Small starter here.
0 · Reply
KalmanFilterX
KalmanFilterX Feb. 4 at 1:48 PM
$GLUE is a clinical-stage biotech focused on inflammatory and fibrotic diseases; its pipeline is in early development, making it a high-risk, binary investment.
1 · Reply
juice_rock
juice_rock Jan. 30 at 5:50 PM
$GLUE About 82% institutional owned and almost 100% long. https://fintel.io/so/us/glue I see every reason to continue holding long term.
0 · Reply
LabPsycho
LabPsycho Jan. 28 at 3:57 PM
$GLUE @dylirious CEOs selling rarely is a good look. But I will give him a pass due to 500% gain in the stock in a few months and closing a great deal. But it , plus the large offering likely will put a damper on the stock and suggests to me nothing major is going to unfold in the next few months. I expect the stock to do a significant retrace before possibly climbing to $30 but that's many months away and a lot will happen in the overall market before then is my guess. As I have posted before I am thinking GLUE could be between 10 and 30 over the next year. The "executive sells are predetermined" is a great argument investors use to gaslight themselves to ignore the likely future trend of the stock. Good luck
0 · Reply
juice_rock
juice_rock Jan. 26 at 4:20 PM
$GLUE Will continue holding. $1.75 Billion market cap with $10 Billion in signed agreements upon milestones. And the last two interims are good data.
0 · Reply
JFais
JFais Jan. 23 at 1:09 PM
This week in Chat: -A number of interesting setups shared in our Non-Biotech channel, including Crypto & Tokenization side of things -Good back and forth on $CRVS, quite a few people owned into the data (vs selling early like I did 🤦‍♂️). Implications for evolving atopic dermatitis landscape & increased market penetration estimates (IF data holds up in higher N of patients). Not to mention impact on confidence level into pivotal PTCL readout and potential to soon move forward in expansion indications like asthma & HS). IP to 2042= long-lived per CEO but others think it's only to 2037 (plenty of time to develop soquelitinib in other indications as well as move next-gen ITK inhibitors forward) Also, noteworthy discussions in $GLUE, $CELC, $VIR, $AVBP among others
0 · Reply
oneyedjacks
oneyedjacks Jan. 22 at 8:52 PM
$GLUE Low volume day, but damn
0 · Reply
MuchMillions
MuchMillions Jan. 22 at 7:21 PM
$GLUE most likely sideways until the conference late February
0 · Reply
nbkihy8
nbkihy8 Jan. 22 at 3:54 PM
$GLUE I'm expecting the next leg up will happen these next few weeks. Prepare for $30 plus
0 · Reply
JFais
JFais Jan. 21 at 9:37 PM
Speaking of missed binaries $WVE $CRVS As well as blow-ups or stocks that ran without us (seeing $GLUE & $ERAS among those currently discussed in Chat) Was one reason I recorded video below (too many ppl being too hard on themselves vs simply live & learn, apply going forward)
0 · Reply
oneyedjacks
oneyedjacks Jan. 21 at 7:28 PM
$GLUE can anyone see this beyond the pay wall?1 https://finance.yahoo.com/m/03c3bd97-33c1-3e5b-b7d1-ef399f0928fc/staar-surgical-alumis-and.html
0 · Reply
Eroc
Eroc Jan. 21 at 3:54 PM
$GLUE I'm ready for the next leg up! Let's go bulls!
0 · Reply
MuchMillions
MuchMillions Jan. 21 at 2:34 PM
0 · Reply